COSA 2014* , ,
Presentations this author is a contributor to:
Nivolumab and ipilimumab in first-line non-small-cell lung carcinoma (NSCLC): interim phase I results (#294)
3:00 PM
Scott J Antonia
Poster discussion 1
Nivolumab in patients with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. (#299)
3:00 PM
Julie R Brahmer
Poster discussion 1
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-Programmed Death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (#412)
3:00 PM
Mario Sznol
Poster discussion 2